Barely Significant
← all excerpts

Targeted agents in patients with progressive glioblastoma-A systematic meta-analysis of randomized clinical trials.

Cancer Med · 2024 · PMC11192969 · PMID 39618405

Europe PMCDOI
1
hedged sentence
0.0800
closest p · 1.6× alpha
0.0800
boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)
In the experimental treatment versus bevacizumab subgroup, all studies failed to show a significant improvement of PFS, although HDAC‐inhibition with vorinostat and bevacizumab 37 showed a trend towards prolonged PFS (RR 0.63, 95% CI 0.37–1.06; p = 0.08; n = 85).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.